Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: A multicenter trial of the adult aids clinical trials group

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 3, 2003, Pages 329-335

  Shiramizu, Bruce ^a,l   Theodore, Dickens ^b   Bassett, Roland ^c   Coel, Marc ^a   Sherman, Kenneth E ^d   Glesby, Marshall J ^e   Chow, Dominic ^a   Alston, Beverly ^f   Colquhoun, Dodi ^g   Merigan Jr , Thomas C ^h   Reichman, Richard C ⁱ   Berggren, Ruth ^j   Burning, Wendy Jo ^g   Brobst, Susan ^k  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j TULANE UNIVERSITY   (United States)

^k SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^l Young Building ^*  (United States)

more..

Author keywords

Hepatitis C virus; HIV; Liver biopsy alternatives; Single photon emission computed tomograph (SPECT)

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARD;

EID: 0038163768     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200307010-00006     Document Type: Article

References (31)

1. Rosenberg PM. Hepatitis C: a hepatologist's approach to an infectious disease. Clin Infect Dis. 2001;33:1728-1732.
2. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol. 2000;14:543-548.
3. Hayashi PH, Flynn N, McCurdy SA, et al. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol. 1991;33:177-180.
4. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 2002;16:813-828.
5. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis. 2002;34:1259-1263.
6. Hernandez-Aguado I, Ramos-Rincon JM, Avinio MJ, et al. Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users. Eur J Epidemiol. 2001;17:539-544.
7. Fernandez I, Rubio R, Lumbreras C. Hepatitis C in HIV-infected patients - therapeutic approach. Clin Microbiol Infect. 2002;8:80-84.
8. Trimoulet P, Neau D, Le Bail B, et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. J Med Virol. 2002;67:143-151.
9. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477-481.
10. Teare JP, Sherman D, Greenfield SM, et al. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet. 1993;342:895-898.
11. Wong VS, Hughes V, Trull A, et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998;5:187-192.
12. Poynard T, Imbert-Bismut F, Ratziu V, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9:128-133.
13. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-1075.
14. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology. 1997;113:1609-1616.
15. Delcourt E, Vanhaeverbeek M, Binon JP, et al. Emission tomography for assessment of diffuse alcoholic liver disease. J Nucl Med. 1992;33:1337-1344.
16. Chung R, Anderson J, Alston B, et al. A randomized, controlled trial of pegylated interferon-alpha-2a with ribavirin vs interferon-alpha-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
18. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
19. Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees. In Wadsworth, ed. Classification and regression trees. 1984:358.
20. Van Heertum RL, Yudd AP, Brunetti JC, et al. Hepatic SPECT imaging in the detection and clinical assessment of hepatocellular disease. Clin Nucl Med. 1992;17:948-953.
21. Iwasa M, Nakamura K, Nakagawa T, et al. Single photon emission computed tomography to determine effective hepatic blood flow and intrahepatic shunting. Hepatology. 1995;21:359-365.
22. Triger DR, Bialas MC, Segasby CA, et al. Hepatic reticuloendothelial function: a correlation of radioisotopic and immunohistochemical assessment. Liver. 1989;9:86-92.
23. Strauss L, Bostel F, Clorius JH, et al. Single-photon emission computed tomography (SPECT) for assessment of hepatic lesions. J Nucl Med. 1982;23:1059-1065.
24. Coleman RE, Blinder RA, Jaszczak RJ. Single photon emission computed tomography (SPECT). Part II: clinical applications. Invest Radiol. 1986;21:1-11.
25. Jaszczak RJ, Coleman RE. Single photon emission computed tomography (SPECT). Principles and instrumentation. Invest Radiol. 1985;20:897-910.
26. Imaeda T, Kanematsu M, Asada S, et al. Utility of Tc-99m GSA SPECT imaging in estimation of functional volume of liver segments in health and liver diseases. Clin Nucl Med. 1995;20:322-328.
27. Hoefs JC, Wang F, Kanel G, et al. The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology. 1995;22:1113-1121.
28. Matsuzaki S, Onda M, Tajiri T, et al. Hepatic lobar differences in progression of chronic liver disease: correlation of asialoglycoprotein scintigraphy and hepatic functional reserve. Hepatology. 1997;25:828-832.
29. Brown JJ, Naylor MJ, Yagan N. Imaging of hepatic cirrhosis. Radiology. 1997;202:1-16.
30. Benhamou Y, Myers RP, Bochet M, et al. Serum biochemical markers of liver fibrosis in HIV and HCV co-infected patients. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, 2002.
31. Laurin J. Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. Can J Gastroenterol. 2002;16:722-726.